drugset
Drugs / Grastek
last change Feb 2018 re-read 3 minutes ago

Grastek

Other / unclassified

Developed for
allergic disease
Investigated by
Merck Sharp & Dohme LLC · Queen's University · Virginia Commonwealth University

Trials 2

today NCT02676765 · Ph 3 NCT02394600 · Ph 4
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 31 trial
Phase 3 NCT02676765 Jun 2016 → Jan 2018 — Virginia Commonwealth University Terminated No outcome recorded
Phase 41 trial · 1 missed
Phase 4 NCT02394600 Apr 2015 → Apr 2016 allergic disease Queen's University Completed Missed primary

Press releases naming this drug 3 releases

DateIssuerRelease
2014-04-14 Merck Sharp & Dohme LLC FDA Approves Merck’s GRASTEK® (Timothy Grass Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Grass Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Children and Adults merck.com ↗
2014-02-03 Merck Sharp & Dohme LLC Merck Announces Canadian Approval of GRASTEK® (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet) merck.com ↗
2013-12-12 Merck Sharp & Dohme LLC Merck Statement on FDA Advisory Committee for GRASTEK® (Timothy Grass Pollen Allergen Extract), Merck’s Investigational Sublingual Allergy Immunotherapy Tablet merck.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Grastek “Grastek” NCT02676765 ↗
1

NCT02394600 ↗
Modality Other / unclassified “Timothy grass pollen allergen extract tablets (Grastek) are standardized sublingual immunotherapy tablets (SLIT-T)” PMID 29432967 ↗ Feb 2018
Route Other “standardized sublingual immunotherapy (SLIT) tablet” NCT02394600 ↗